NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc. is a biopharmaceutical company focused on commercializing and developing its nonantibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market. The company's Neutrox family of products includes Avenova for the eye care market, Neutrophase for wound care market and CelleRx for the cosmetic surgery and aesthetic dermatology market; they have been cleared by the U.S. FDA as 510(k) medical devices. NovaBay's other focuses are its Aganocide compounds, led by Auriclosene, which is in development as a new drug in urology and dermatology. NovaBay is partnered in the U.S. and around the globe.

Expert Comments:

Jason Kolbert, Maxim Group (8/19/15)
"Novabay Pharmaceuticals Inc. reported the quarter with revenues of $1M (from its main product, Avenova) reflecting the early stages of the product launch. . .the company has announced plans to expand the sales reps from 35 to 50 by the end of September. Novabay announced 510(k) clearance from the FDA to market its new high-tech device, intelli-Case, for safely disinfecting contact lenses with hydrogen peroxide. We have not factored this into our model (yet)."

Management Q&A: View From the Top
Ron Najafi
What a difference just nine months can make. In this interview, NovaBay Pharmaceuticals' Founder, President and CEO Dr. Ramin "Ron" Najafi talks about his company's turnaround and how he is steering the product portfolio toward a hockey-stick sales growth curve.
read more >
Jason Kolbert, Maxim Group (6/4/15)
"This morning, NovaBay Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the company's new high-tech device, intelli-Case, for safely disinfecting contact lenses with hydrogen peroxide. This is a 510(k) clearance from the FDA to market its novel intelli-Case with hydrogen peroxide solutions."

Edward Woo, Ascendiant Capital Markets (5/20/15)
"We attended the NovaBay Pharmaceuticals Inc. analyst event in New York and came away with a continued positive view on the company. . .despite recent stock volatility and weakness, we believe the company represents an interesting investment story as it is transitioning into a more product-focused company. Initial product reception for Avenova is positive, and though we acknowledge that it is still at a very early stage, we believe the $600M market potential presents a high reward for the risks."

Yale Jen, Laidlaw & Company (5/20/15)
"We are very encouraged by NovaBay Pharmaceuticals Inc.'s Avenova sales in Q1/15 and expect sales to continue to expand in 2015 and beyond. . .we believe the compay is preparing to conduct relatively inexpensive Phase 4 studies to further demonstrate the effectiveness of Avenova. Positive outcomes from such studies could be a valuable tool to gain further physician buy-in in addition to the current peer-to-peer discussions on the benefits of Avenova."

Jason Kolbert, Maxim Group (4/29/15)
"We are assuming coverage of NovaBay Pharmaceuticals Inc. with a Buy rating. . .the company's family of products kills a broad spectrum of bacteria quickly and completely, and destroy the damage-causing toxins the bacteria produce. . .we see now as an opportunity for investors to build positions before sales accelerate and valuation increases."

Yale Jen, Laidlaw & Company (3/27/15)
"Pioneer Pharma Holdings has launched promotion activities for NovaBay Pharmaceuticals Inc.'s NeutroPhase skin and wound cleanser in China in March, 2015. Given the vast market and unmet medical needs in China, long-term NeutroPhase sales could potentially reach $300M."

More Expert Comments

Experts Commenting on This Company

Yale Jen, Analyst – Laidlaw & Company
Jason Kolbert, Senior Analyst – Maxim Group
Edward Woo – Ascendiant Capital Markets

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
NovaBay Pharmaceuticals Inc. Content